tm2623944-1_424b5 - none

424B5 1 tm2623944-1_424b5.htm 424B5 tm2623944-1_424b5 - none - 4.034825s

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-291520

PROSPECTUS SUPPLEMENT
(To Prospectus dated December 8, 2025)

Up to $50,000,000

[MISSING IMAGE: lg_coherusoncology-4c.jpg]

Common Stock

We entered into a sales agreement with Leerink Partners LLC, or Leerink Partners, dated as of August 28, 2026, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospectus.

Our common stock is listed on the Nasdaq Global Market under the symbol “CHRS.” On August 27, 2026, the last reported sale price of our common stock on the Nasdaq Global Market was $1.46 per share.

Subject to the terms and conditions of the sales agreement, Leerink Partners may sell the common stock by any methods deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on the Nasdaq Global Market, or as otherwise agreed upon by Leerink Partners and us. Leerink Partners is not required to sell any specific amount of securities, but will act as sales agent using its commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Leerink Partners and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to Leerink Partners for sales of common stock sold pursuant to the sales agreement will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Leerink Partners will be deemed to be underwriting commissions or discounts. We have agreed to reimburse Leerink Partners for certain of its out-of-pocket expenses. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Investing in our common stock involves a high degree of risk. Before making an investment decision, please read the information under “Risk Factors” beginning on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

Leerink Partners

The date of this prospectus supplement is August 28, 2026.

	ABOUT THIS PROSPECTUS SUPPLEMENT					S-1
	PROSPECTUS SUPPLEMENT SUMMARY					S-3
	RISK FACTORS					S-5
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS					S-7
	USE OF PROCEEDS					S-9
	PLAN OF DISTRIBUTION					S-10
	LEGAL MATTERS					S-11
	EXPERTS					S-12
	WHERE YOU CAN FIND MORE INFORMATION					S-13
	INFORMATION INCORPORATED BY REFERENCE					S-14

	ABOUT THIS PROSPECTUS					1
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS					2
	WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE					4
	THE COMPANY					6
	RISK FACTORS					7
	USE OF PROCEEDS					8
	DESCRIPTION OF CAPITAL STOCK					9
	DESCRIPTION OF DEBT SECURITIES					13
	DESCRIPTION OF WARRANTS					20
	DESCRIPTION OF UNITS					21
	GLOBAL SECURITIES					22
	PLAN OF DISTRIBUTION					26
	LEGAL MATTERS					28
	EXPERTS					29